Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook

ASAQ Product Profile - Overview

ASAQ to treat malaria

= Fixed dose combination of Artesunate + Amodiaquine

  • Launched in 2007
  • The concrete results of an innovative partnership between DNDi and Sanofi
  • Meets the latest WHO guidelines for malaria treatment in Africa
  • Simple regimen: 1 or 2 tablets once a day for 3 days
  • Available at only 0.5$ for children, 1$ for adults
  • Meets the highest standard of quality
  • Made in the South for use in the South: ASAQ is produced in Marocco
  • Available under the name Artesunate-Amodiaquine Winthrop (ASAQ) for public market and Coarsucam for private market
  • Handed over to the MMV Access and Product Management team in May 2015 to help maximize patient access - read statement

Download ASAQ Press pack, March 1st 2007 [PDF 890KB]
Download ASAQ Newsletter, November 2009 [PDF 980KB]
Read more about ASAQ project
  ASAQ News
Implementation progress

Handed over to MMV Access team

More than 400 million treatments distributed

ASAQ registered in 35 countries & territories

Technology transfer to African industry partner ongoing
Key Scientific Publications
BMC Medicine, March 2015
The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data
Malaria Journal, December 2014

Fixed dose artesunate amodiaquine - a phase IIb, randomized comparative trial with non-fixed artesunate amodiaquine
Malaria Journal, March 2014

Plasmodium falciparum clearance in clinical studies of artesunate-amodiaquine and comparator treatments in sub-Saharan Africa, 1999–2009
Malaria Journal, July 2013
Efficacy of ASAQ and AL fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial 
Malaria Journal, July 2013
Tolerability and safety of ASAQ and AL fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Nimba County, Liberia
Malaria Journal, July 2009
Randomized, multicentre assessment of the efficacy and safety of ASAQ – a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria
Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site
is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License